Phase II Study of Combination Rituxan (Rituximab, Mabthera) and Fludarabine Therapy in Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia)
- Determine the objective response and time to treatment failure in patients with
Waldenstrom's macroglobulinemia treated with rituximab and fludarabine.
- Determine the toxicity of this regimen in these patients.
- Determine if molecular remissions are achievable in patients attaining a clinical
complete response when treated with this regimen.
OUTLINE: This is a multicenter study.
Patients receive rituximab IV over 3-6 hours once weekly on weeks 1-4, 17, 18, 30, and 31
and fludarabine IV over 10-30 minutes once daily for 5 days on weeks 5, 9, 13, 19, 23, and
Patients are followed at least every 2 months for 2 years.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
Primary Purpose: Treatment
Christos E. Emmanouilides, MD
Jonsson Comprehensive Cancer Center
United States: Federal Government
|Arizona Cancer Center||Tucson, Arizona 85724|
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|
|Jonsson Comprehensive Cancer Center, UCLA||Los Angeles, California 90095-1781|
|Walter Reed Army Medical Center||Washington, District of Columbia 20307-5000|
|Rush-Presbyterian-St. Luke's Medical Center||Chicago, Illinois 60612|
|Massachusetts General Hospital Cancer Center||Boston, Massachusetts 02114|
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|
|Cedars-Sinai Medical Center||Los Angeles, California 90048|
|Cleveland Clinic Taussig Cancer Center||Cleveland, Ohio 44195|
|Holden Comprehensive Cancer Center||Iowa City, Iowa 52242-1009|
|Marlene and Stewart Greenebaum Cancer Center, University of Maryland||Baltimore, Maryland 21201-1595|
|Tuft-New England Medical Center||Boston, Massachusetts 02111|
|Barrett Cancer Center||Cincinnati, Ohio 45267-0502|
|Long Island Jewish Medical Center||New Hyde Park, New York 11040|